Evidence mapPaperPMID 28493515Full record

ReviewDiabetes, obesity & metabolism2018

Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.

Tamara S Hannon, Steven E Kahn, Kristina M Utzschneider, Thomas A Buchanan, Kristen J Nadeau, Philip S Zeitler, David A Ehrmann, Silva A Arslanian, Sonia Caprio, Sharon L Edelstein and 3 more

2 registry-linked trialsAbstract readComparative StudyReview
In one paragraph

Review in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01779362. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01779362 phase3completed

Restoring Insulin Secretion Adult Medication Study

Ran2013Enrolled267Registered outcomes4Posted comparisons4ConditionsPrediabetes, Type 2 DiabetesArmsGlargine, liraglutide, Metformin, Placebo
PMID 24194506other papers from this trial
Open the trial in the graph
NCT01779375 phase3completed

Restoring Insulin Secretion Pediatric Medication Study

Ran2013Enrolled91Registered outcomes6Posted comparisons3ConditionsPrediabetes, Type 2 DiabetesArmsGlargine, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Metformin monotherapy for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020 · on this map
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tamara S HannonDepartments of Pediatrics (T. S. H.) and Medicine (K. J. M.), Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0002-8792-4278
Steven E KahnVA Puget Sound Health Care System and Department of Medicine, University of Washington, Seattle, Washington.
Kristina M UtzschneiderVA Puget Sound Health Care System and Department of Medicine, University of Washington, Seattle, Washington.
Thomas A BuchananUniversity of Southern California Keck School of Medicine/Kaiser Permanente Southern California, Department of Medicine, Los Angeles, California.
Kristen J NadeauUniversity of Colorado Denver/Children's Hospital Colorado, Department of Pediatrics, Denver, Colorado.
Philip S ZeitlerUniversity of Colorado Denver/Children's Hospital Colorado, Department of Pediatrics, Denver, Colorado.
David A EhrmannUniversity of Chicago, Chicago, Illinois.
Silva A ArslanianChildren's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Department of Pediatrics, Pittsburgh, Pennsylvania.
Sonia CaprioDepartment of Pediatrics, Yale University, New Haven, Connecticut.
Sharon L EdelsteinGeorge Washington University Biostatistics Center (RISE Coordinating Center), Rockville, Maryland.
Peter J SavageNational Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Maryland.
Kieren J MatherDepartments of Pediatrics (T. S. H.) and Medicine (K. J. M.), Indiana University School of Medicine, Indianapolis, Indiana.
RISE Consortium

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Southern California Clinical and Translational Science InstituteUL1TR001855 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$9.1M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · UNIVERSITY OF COLORADO DENVER · 1995 to 2025
$7.7M
Translation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7M
The Next Generation of Innovative Cardiovascular Clinical/Translational ResearchersK24HL145076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI KRISTEN Jane NADEAU · 2022 to 2023
$230k
NCATS NIH HHS UL1 TR001855NHLBI NIH HHS K24 HL145076NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK097512NIDDK NIH HHS U01 DK094406NIDDK NIH HHS U01 DK094430NIDDK NIH HHS U01 DK094431NIDDK NIH HHS U01 DK094438NIDDK NIH HHS U01 DK094467
6 · The paper itself

Abstract

The Restoring Insulin Secretion (RISE) study was initiated to evaluate interventions to slow or reverse the progression of β-cell failure in type 2 diabetes (T2D). To design the RISE study, we undertook an evaluation of methods for measurement of β-cell function and changes in β-cell function in response to interventions. In the present paper, we review approaches for measurement of β-cell function, focusing on methodologic and feasibility considerations. Methodologic considerations included: (1) the utility of each technique for evaluating key aspects of β-cell function (first- and second-phase insulin secretion, maximum insulin secretion, glucose sensitivity, incretin effects) and (2) tactics for incorporating a measurement of insulin sensitivity in order to adjust insulin secretion measures for insulin sensitivity appropriately. Of particular concern were the capacity to measure β-cell function accurately in those with poor function, as is seen in established T2D, and the capacity of each method for demonstrating treatment-induced changes in β-cell function. Feasibility considerations included: staff burden, including time and required methodological expertise; participant burden, including time and number of study visits; and ease of standardizing methods across a multicentre consortium. After this evaluation, we selected a 2-day measurement procedure, combining a 3-hour 75-g oral glucose tolerance test and a 2-stage hyperglycaemic clamp procedure, augmented with arginine.

Indexed as

Models, BiologicalResearch DesignArginineBiomarkersDiabetes Mellitus, Type 2Glucose Clamp TechniqueGlucose Tolerance TestHumansInfusions, IntravenousInsulinInsulin ResistanceInsulin-Secreting CellsInsulin SecretionPostprandial PeriodArginineBiomarkersInsulinglucose metabolisminsulin resistanceinsulin secretiontype 2 diabetesβ cell

Identifiers

PMID28493515
PMCPMC6095472

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.